References of "MOURAD, Georges"
     in
Bookmark and Share    
Full Text
See detailVascular calcifications in chronic kidney disease: can the Biologist be of some help?
Bargnoux, Anne-Sophie; Morena, Marion; Dupuy, Anne-Marie et al

in DELANAYE, Pierre (Ed.) Clinical Chemistry and Nephrology: the essential link (2012)

Detailed reference viewed: 16 (2 ULg)
Full Text
Peer Reviewed
See detailThe french speaking society of transplantation and "transplantation sans frontières"
SQUIFFLET, Jean-Paul ULg; BARROU, Benoit; GLOTZ, Denis et al

in Transplantation Proceedings (2011), 43

Detailed reference viewed: 21 (2 ULg)
Full Text
Peer Reviewed
See detailDaclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients.
Noel, Christian; Abramowicz, Daniel; Durand, Dominique et al

in Journal of the American Society of Nephrology [=JASN] (2009), 20(6), 1385-92

Nondepleting anti-CD25 monoclonal antibodies (daclizumab) and depleting polyclonal antithymocyte globulin (Thymoglobulin) both prevent acute rejection, but these therapies have not been directly compared ... [more ▼]

Nondepleting anti-CD25 monoclonal antibodies (daclizumab) and depleting polyclonal antithymocyte globulin (Thymoglobulin) both prevent acute rejection, but these therapies have not been directly compared in a high-risk, HLA-sensitized renal transplant population. We randomly assigned 227 patients, who were about to receive a kidney graft from a deceased donor, to either Thymoglobulin or daclizumab if they met one of the following risk factors: current panel reactive antibodies (PRA) >30%; peak PRA >50%; loss of a first kidney graft from rejection within 2 yr of transplantation; or two or three previous grafts. Maintenance immunosuppression comprised tacrolimus, mycophenolate mofetil, and steroids. Compared with the daclizumab group, patients treated with Thymoglobulin had a lower incidence of both biopsy-proven acute rejection (15.0% versus 27.2%; P = 0.016) and steroid-resistant rejection (2.7% versus 14.9%; P = 0.002) at one year. One-year graft and patient survival rates were similar between the two groups. In a comparison of rejectors and nonrejectors, overall graft survival was significantly higher in the rejection-free group (87.2% versus 75.0%; P = 0.037). In conclusion, among high-immunological-risk renal transplant recipients, Thymoglobulin is superior to daclizumab for the prevention of biopsy-proven acute rejection, but there is no significant benefit to one-year graft or patient survival. [less ▲]

Detailed reference viewed: 29 (5 ULg)
Full Text
Peer Reviewed
See detailPremier episode de rejet aigu apres transplantation renale: etude des caracteristiques histopathologiques en fonction du risque immunologique du patient.
Ghisdal, Lidia; Touchard, Guy; Goujon, Jean-Michel et al

in Néphrologie & Thérapeutique (2008), 4(3), 173-80

Renal allograft biopsies (n=34) of two different populations of patients according to the immunological risk (high versus low-risk) have been compared retrospectively. The presence of polymorphonuclear ... [more ▼]

Renal allograft biopsies (n=34) of two different populations of patients according to the immunological risk (high versus low-risk) have been compared retrospectively. The presence of polymorphonuclear leukocytes in peritubular capillaries was more frequent in the high-risk group. The C4d staining was positive in 10% of the low-risk patients and in 50% of the high-risk patients (P=0.03). There were more early graft loss, renal infarctions, interstitial hemorrhage, severe glomerulitis, neutrophilic glomerulitis and Banff III grade rejection in the positive C4d group. In conclusion, half of the immunized patients had a humoral rejection, patients with a C4d positive rejection had more early graft loss and more severe histological lesions. [less ▲]

Detailed reference viewed: 98 (3 ULg)